MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- DR. REDDYS LAB (pharmaceuticals)
- Latest 8 Quarter Result
DR. REDDYS LAB Quarterly Results (REDY)
Here are the latest quarterly results of DR. REDDYS LAB. For more details, see the DR. REDDYS LAB financial fact sheet and DR. REDDYS LAB share price and chart. For a sector overview, read our pharmaceuticals sector report.
DR. REDDYS LAB Quarterly Results
| No. of Mths Qtr. Ending |
3
Dec-19* |
3
Mar-20* |
3
Jun-20* |
3
Sep-20* |
3
Dec-20* |
3
Mar-21* |
3
Jun-21* |
3
Sep-21* |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 43,971 | 44,489 | 44,265 | 49,109 | 49,419 | 47,682 | 49,451 | 57,869 | |
| Other income | Rs m | 673 | 736 | 871 | 512 | 705 | 826 | 1,079 | 2,055 | |
| Turnover | Rs m | 44,644 | 45,225 | 45,136 | 49,621 | 50,124 | 48,508 | 50,530 | 59,924 | |
| Expenses | Rs m | 46,858 | 34,997 | 33,052 | 37,548 | 44,026 | 37,150 | 42,106 | 44,271 | |
| Gross profit | Rs m | -2,887 | 9,492 | 11,213 | 11,561 | 5,393 | 10,532 | 7,345 | 13,598 | |
| Depreciation | Rs m | 2,869 | 2,741 | 2,923 | 3,165 | 3,112 | 3,088 | 2,839 | 2,941 | |
| Interest | Rs m | 152 | 230 | 233 | 252 | 188 | 297 | 193 | 234 | |
| Profit before tax | Rs m | -5,235 | 7,257 | 8,928 | 8,656 | 2,798 | 7,973 | 5,392 | 12,478 | |
| Tax | Rs m | 325 | -449 | 3,059 | 1,011 | 2,670 | 2,579 | 1,754 | 2,767 | |
| Profit after tax | Rs m | -5,560 | 7,706 | 5,869 | 7,645 | 128 | 5,394 | 3,638 | 9,711 | |
| Gross profit margin | % | -6.6 | 21.3 | 25.3 | 23.5 | 10.9 | 22.1 | 14.9 | 23.5 | |
| Effective tax rate | % | -6.2 | -6.2 | 34.3 | 11.7 | 95.4 | 32.3 | 32.5 | 22.2 | |
| Net profit margin | % | -12.6 | 17.3 | 13.3 | 15.6 | 0.3 | 11.3 | 7.4 | 16.8 | |
| Diluted EPS | Rs | -33.4 | 46.3 | 35.3 | 45.9 | 0.8 | 32.4 | 21.9 | 58.4 | |
| Diluted EPS (TTM) | Rs | NA | 118.4 | 114.0 | 94.1 | 128.3 | 114.4 | 101.0 | 113.4 | |
 Subscriber Feature |
||||||||||
Interim results exclude extraordinary / exceptional items
Read: DR. REDDYS LAB 3QFY19 Result Performance Review
More Pharmaceuticals Company Quarterly Results: SUN PHARMA AUROBINDO PHARMA CIPLA PIRAMAL ENTERPRISES LUPIN
Compare DR. REDDYS LAB With: SUN PHARMA AUROBINDO PHARMA CIPLA PIRAMAL ENTERPRISES LUPIN
Today's Market
Indian Indices End Flat Amid Volatility; Asian Paints, Axis Bank & HUL Among Top Losers(Closing)
Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.
Views on news
Dr Reddy's New Covid-19 Treatment Option Puts Stock in Focus (Views On News)
May 24, 2021With the second wave pushing up sales of medicines, Indian pharma companies are likely to see traction in their volumes.
Dr Reddy's Lab Shares Fall As Earnings Miss Estimates. What Next? (Views On News)
May 14, 2021The company's board recommended a final dividend of Rs 25 for financial year 2020-21.
Sun Pharma vs Dr Reddy's: Which is Better? (Views On News)
Dec 16, 2021In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.
5 Indian Pharma Companies Riding the Vaccination Wave (Views On News)
Sep 3, 2021These companies are likely to benefit the most from Covid-19 vaccines.
5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)
Dec 3, 2021As the new variant of Covid-19 emerges, keep an eye on these stocks.
More Views on NewsMost Popular
India's Best Semiconductor Stocks 
(Views On News)
Jan 7, 2022
Modern wars are fought with semiconductors. India's best semiconductor stocks have big tailwinds from defence and manufacturing.
10 Indian Companies with the Fastest Growth in Dividend Payouts... (Views On News)
Jan 10, 2022These companies have been consistently paying higher dividends for several years.
Tata Steel vs SAIL: Which Stock is Better? (Views On News)
Jan 13, 2022With government initiatives set to boost the steel sector, find out who has a better chance of coming out on top.
Looking for Consistent Compounding Stocks? Here's a Watchlist for You (Views On News)
Jan 6, 2022These companies have generated mind boggling returns for investors over the years.
My Best Sectors for 2022 (Fast Profits Daily)
Jan 4, 2022My top 2 sectors for 2022 might surprise you.
MoreOUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2022
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: How to Profit from Sensex 100,000
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
DR. REDDYS LAB SHARE PRICE
Jan 14, 2022 (Close)
TRACK DR. REDDYS LAB
- Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON DR. REDDYS LAB
DR. REDDYS LAB 5-YR ANALYSIS
COMPARE DR. REDDYS LAB WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
FOLLOW
APP
EQUITYMASTER SUPPORTS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.